Pretax income is the income that a company earns before paying income taxes. Cara Therapeutics's pretax income for the
three
months ended in Dec. 2023 was $-32.34 Mil.
Its pretax income for the trailing twelve months (TTM) ended in Dec. 2023 was $-118.51 Mil.
Cara Therapeutics's pretax margin was -1,076.46%.
During the past 13 years, Cara Therapeutics's highest Pretax Margin was 5.71%. The lowest was -67148.84%. And the median was -558.63%.
Cara Therapeutics Pre-Tax Income Historical Data
The historical data trend for Cara Therapeutics's Pre-Tax Income can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Competitive Comparison of Cara Therapeutics's Pre-Tax Income
For the Biotechnology subindustry, Cara Therapeutics's Pre-Tax Income, along with its competitors' market caps and Pre-Tax Income data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Cara Therapeutics's Pre-Tax Income Distribution in the Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Cara Therapeutics's Pre-Tax Income distribution charts can be found below:
* The bar in red indicates where Cara Therapeutics's Pre-Tax Income falls into.
Cara Therapeutics Pre-Tax Income Calculation
This is the income that a company earns before paying income taxes.
Cara Therapeutics's Pretax Income for the fiscal year that ended in Dec. 2023 is calculated as
Pre-Tax Income for the trailing twelve months (TTM) ended in Dec. 2023 adds up the quarterly data reported by the company within the most recent 12 months, which was $-118.51 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Cara Therapeutics (NAS:CARA) Pre-Tax Income Explanation
Cara Therapeutics's Pretax Margin for the quarter that ended in Dec. 2023 is calculated as
During the past 13 years, Cara Therapeutics's highest Pretax Margin was 5.71%. The lowest was -67148.84%. And the median was -558.63%.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Cara Therapeutics Pre-Tax Income Related Terms
Thank you for viewing the detailed overview of Cara Therapeutics's Pre-Tax Income provided by GuruFocus.com. Please click on the following links to see related term pages.
Cara Therapeutics (Cara Therapeutics) Business Description
Cara Therapeutics Inc is an emerging biotechnology company involved in the development of novel therapeutics to treat human diseases associated with inflammation, pain, and pruritus. Cara's most advanced compound, CR845, aims to treat acute pain and pruritus. This patented compound has analgesic, anti-inflammatory, and antipruritic properties that can be used for multiple therapeutic applications. Additionally, Cara's objective is to use its proprietary drug-screening technology to develop a future pipeline of first-in-class molecules with analgesic and anti-inflammatory features.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
Portfolio Contest
CARA has been successfully added to your 